Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.50-1.83 (-3.95%)
At close: 4:00 PM EDT

44.35 -0.19 (-0.43%)
After hours: 7:50 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close46.33
Bid42.65 x 100
Ask44.68 x 500
Day's Range44.36 - 46.54
52wk Range8.00 - 63.73
1y Target EstN/A
Market Cap2.35B
P/E Ratio (ttm)-8.31
Avg Vol (3m)4,087,323
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Forbes9 hours ago

    After 'Female Viagra,' Muscular Dystrophy Drug, Will FDA Stand Firmer Against Pressure To Approve?

    The FDA has approved at least two drugs recently that critics and some agency staff lacked adequate evidence of safety and effectiveness. As a result, will the agency become more forceful in urging drug makers to conduct better studies?

  • Forbes15 hours ago

    The Challenge Of Providing Early Access To Potential Life-Saving Drugs

    Let’s not use the eteplirsen approval as a way to lobby for new ways to put constraints on the biopharmaceutical industry.

  • Barrons.comyesterday

    Sarepta: 'Setting Aside the Controversy Around the Questionable Data…'

    After meeting with Sarepta Therapeutics' (SRPT) management, Leerink's Joseph Schwartz and Dae Gon Ha offer an update on the company but can't help including a dig at the company's Duchenne muscular dystrophy treatment, which was recently approved by the FDA. From their note: Setting aside the controversy around the questionable data and basis for approval, the FDA’s blessing has shifted investors’ theses on the stock, which has now become a commercial execution and potential takeover story. Of course, there's always the question of who will pay for Sarepta's pricey drug: Despite Anthem’s (ANTM)) announcement that they will deny coverage, Sarepta still believes payors (including Anthem) will eventually cover Exondys 51.